132 related articles for article (PubMed ID: 23411443)
21. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
22. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
25. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
27. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
29. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
30. Gene-based strategies for the immunotherapy of cancer.
Tüting T; Storkus WJ; Lotze MT
J Mol Med (Berl); 1997 Jul; 75(7):478-91. PubMed ID: 9253711
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma.
Kuriyama H; Fukushima S; Kimura T; Kanemaru H; Miyashita A; Okada E; Kubo Y; Nakahara S; Tokuzumi A; Nishimura Y; Kajihara I; Makino K; Aoi J; Masuguchi S; Tsukamoto H; Inozume T; Zhang R; Nakatsura T; Uemura Y; Senju S; Ihn H
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669419
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE).
Dickhaut K; Hoepner S; Eckhard J; Wiesmueller KH; Schindler L; Jung G; Falk K; Roetzschke O
PLoS One; 2009 Sep; 4(9):e6811. PubMed ID: 19738910
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
Beyranvand Nejad E; Labrie C; van der Sluis TC; van Duikeren S; Franken KLMC; Roosenhoff R; Arens R; van Hall T; van der Burg SH
Int J Cancer; 2021 Jan; 148(1):211-225. PubMed ID: 32875568
[TBL] [Abstract][Full Text] [Related]
35. A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer.
Shimizu M; Matsuzawa A; Takeda Y
Mol Biotechnol; 2003 Sep; 25(1):89-94. PubMed ID: 13679639
[TBL] [Abstract][Full Text] [Related]
36. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
37. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
39. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.
Iwama T; Horie K; Yoshikawa T; Nobuoka D; Shimomura M; Sawada Y; Nakatsura T
Int J Oncol; 2013 Mar; 42(3):831-8. PubMed ID: 23354275
[TBL] [Abstract][Full Text] [Related]
40. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
Front Immunol; 2018; 9():650. PubMed ID: 29670624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]